The MHRA can step in if a supplement is marketed as treating a disease or modifying a body function in a way that crosses into medicinal territory
Currently, it is indicated for patients with a BMI greater than 30% or a BMI greater than 27% with comorbidities
Safety profiles are equivalent when manufactured under these rigorous conditions
Ozempic and Wegovy maker sues over compounded, off-brand versions of drugs used for weight loss Novo Nordisk, the pharmaceutical company that makes Ozempic and Wegovy, filed multiple lawsuits Tuesday against off-brand versions of the wildly popular drugs
These medications include semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), tirzepatide (Mounjaro, Zepboundwhich also targets GIP receptors), and several others